COL6A2 drives clear cell renal cell carcinoma progression via integrin-dependent modulation of Wnt/β-catenin signaling
Journal of Cancer · 2025-11-14 · 16 (15) · 4426-4439
DOI: 10.7150/jca.120607 ↗At a glance
Journal article in Journal of Cancer, published on 2025-11-14. Written by Xing Ji and 6 co-authors. Institution: Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China. Cited 2 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Introduction
The mechanistic role of COL6A2, an extracellular matrix protein, in clear cell renal cell carcinoma (ccRCC) is largely unexplored. This study aimed to investigate COL6A2 expression, its prognostic value, biological functions, and underlying molecular mechanisms in ccRCC.
Methods
COL6A2 expression was analyzed in ccRCC tissues and cell lines using public datasets and Western blotting on clinical samples and cell lines. Prognostic associations were evaluated using TCGA-KIRC data via clinicopathological correlations, Kaplan-Meier survival, and Cox regression analyses. Functional effects of COL6A2 knockdown in ccRCC cells were assessed by CCK-8, wound healing, Transwell, and Western blot analysis of EMT-associated proteins. Mechanistic investigations involved bioinformatic analysis, co-immunoprecipitation, Western blotting for Wnt/β-catenin pathway proteins, integrin blockade, and rescue experiments with the Wnt/β-catenin activator.
Results
COL6A2 mRNA and protein were significantly upregulated in ccRCC tissues and cell lines. High COL6A2 expression correlated with aggressive clinicopathological features and independently predicted poorer prognosis. COL6A2 knockdown significantly inhibited ccRCC cell proliferation, migration, invasion, and reversed epithelial-mesenchymal transition (EMT). Mechanistically, COL6A2 was found to physically interact with integrin β1, thereby activating the Wnt/β-catenin signaling pathway to induce EMT. Rescue experiments confirmed the role of this signaling axis in mediating the malignant phenotypes.
Conclusion
COL6A2 promotes ccRCC aggressiveness and modulates Wnt/β-catenin signaling in an integrin-dependent manner. These findings nominate the COL6A2-integrin interface as a potential therapeutic and biomarker axis in ccRCC.
Subjects
Author keywords
Authors and institutions
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
- Department of Urology, Peking University First Hospital, Beijing, 100034, China.
- Institution of Urology, Peking University, Beijing, 100034, China.
- National Urological Cancer Center, Beijing, 100034, China.
- Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China.
Cite
APA
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2025). COL6A2 drives clear cell renal cell carcinoma progression via integrin-dependent modulation of Wnt/β-catenin signaling. Journal of Cancer, 16(15), 4426-4439. https://doi.org/10.7150/jca.120607
Vancouver
Ji X, Yun Y, Zhu Z, Wu T, Ruan M, Fan Y, et al. COL6A2 drives clear cell renal cell carcinoma progression via integrin-dependent modulation of Wnt/β-catenin signaling. Journal of Cancer. 2025;16(15):4426-4439. doi:10.7150/jca.120607
BibTeX
@article{Ji2025,
author = {Ji, Xing and Yun, Yongyang and Zhu, Zhenpeng and Wu, Tianyu and Ruan, Mingjian and Fan, Yu and Zhang, Qian},
title = {COL6A2 drives clear cell renal cell carcinoma progression via integrin-dependent modulation of Wnt/β-catenin signaling},
journal = {Journal of Cancer},
year = {2025},
volume = {16},
number = {15},
pages = {4426--4439},
doi = {10.7150/jca.120607}
}
EUVIMED